H.C. Wainwright analyst Andrew Fein maintained a Buy rating on Arvinas Holding Company (NASDAQ:ARVN) on Friday, setting a price target of $135, which is approximately 59.74% above the present share price of $84.51.
Fein expects Arvinas Holding Company to post earnings per share (EPS) of -$0.84 for the third quarter of 2021.
The current consensus among 8 TipRanks analysts is for a Strong Buy rating of shares in Arvinas Holding Company, with an average price target of $123.13.
The analysts price targets range from a high of $170 to a low of $105.
In its latest earnings report, released on 03/31/2021, the company reported a quarterly revenue of $5.54 million and a net profit of -$41.65 million. The company's market cap is $4.14 billion.
According to TipRanks.com, H.C. Wainwright analyst Andrew Fein is currently ranked with 5 stars on a 0-5 stars ranking scale, with an average return of 16.5% and a 47.87% success rate.
Arvinas, Inc. is a biopharmaceutical company, which engages in the discovery, development and commercialization of therapies to degrade disease-causing proteins. Its lead products include ARV-110 and ARV-471. The company was founded in February 2013 and is headquartered in New Haven, CT.